Cas:210694-00-1 1-(2,2-Dimethylpropoxy)-2-nitrobenzene manufacturer & supplier

Chemical Name:1-(2,2-Dimethylpropoxy)-2-nitrobenzene

CAS.NO:210694-00-1

Synonyms:o-neopentoxynitrobenzene

Molecular Formula:C₁₁H₁₅NO₃

Molecular Weight:209.24200

HS Code:2909309090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:55.05000

Exact Mass:209.10500

LogP:3.54290

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like o-neopentoxynitrobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,o-neopentoxynitrobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,o-neopentoxynitrobenzene Use and application,o-neopentoxynitrobenzene technical grade,usp/ep/jp grade.

Related News: Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey. 1-(2,2-Dimethylpropoxy)-2-nitrobenzene manufacturer The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study. 1-(2,2-Dimethylpropoxy)-2-nitrobenzene supplier Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey. 1-(2,2-Dimethylpropoxy)-2-nitrobenzene vendor Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms. 1-(2,2-Dimethylpropoxy)-2-nitrobenzene factory The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study.